Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04188535 | Serial MRI Scans During Radiation Therapy(RELAY) | recruiting | N/A | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | recruiting | — | 2,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 |
| NCT06632977 | Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial(PREDICT) | recruiting | Phase 2 | 474 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06931340 | Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | recruiting | Phase 3 | 1,260 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06995898 | The Vanguard Study: Testing a New Way to Screen for Cancer | recruiting | N/A | 24,000 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07192614 | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer(ACTIVATED-4-PC) | recruiting | Phase 1 / Phase 2 | 52 | AstraZenecaINDUSTRY | 9 | Sep 2, 2026 | clinicaltrials |
| NCT07200830 | Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial | recruiting | Phase 3 | 1,524 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05647564 | PET/CT Characterization of Treatment Resistance | recruiting | N/A | 25 | University of Wisconsin, MadisonOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05710380 | MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy | recruiting | N/A | 180 | University of ChicagoOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07162194 | MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial | recruiting | N/A | 130 | University of Southern CaliforniaOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07798778 | Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer(SRT-017-001) | recruiting | Early Phase 1 | 18 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05726292 | A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer | recruiting | Phase 2 | 90 | University of ChicagoOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05942001 | Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | recruiting | Phase 1 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06600698 | Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA | recruiting | Phase 1 / Phase 2 | 45 | Milton S. Hershey Medical CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06654336 | Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)(RATIONAL) | recruiting | Phase 2 | 162 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07111507 | A Study of Tarlatamab for People With Prostate Cancer | recruiting | Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07795723 | Ipsilateral Versus Bilateral Systematic Biopsy Combined With MRI/Ultrasound Cognitive Fusion Targeted Biopsy for Prostate Cancer Diagnosis(IBIS-PC) | recruiting | N/A | 454 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06854250 | Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer | recruiting | Phase 2 | 104 | Sun Yat-sen UniversityOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07054346 | Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617(LUTACT) | recruiting | Phase 1 | 45 | Thomas HopeOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07218666 | Zanzalintinib in Men With Aggressive Variant Prostate Cancer(NAPOLEON) | recruiting | Phase 2 | 30 | Deepak KilariOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07782164 | Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)(PELFIRE) | recruiting | — | 27 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07790718 | Testing the Effects of Exercise on Colorectal Cancer Development After Treatment With Pelvic Radiation Therapy for Prostate Cancer | recruiting | N/A | 30 | City of Hope Medical CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07792590 | Registry for Prostate Cancer Focal Therapy | recruiting | — | 200 | The University of Hong KongOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07792993 | Focal Micro-boost Strategy in Patients With Intermediate- to High-risk Prostate Cancer (IR-HR PCa) Undergoing Hypofractionated Radiotherapy(62SPECIAL) | recruiting | — | 82 | Regina Elena Cancer InstituteOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04589468 | Researching the Effect of Exercise on Cancer | recruiting | N/A | 51 | City of Hope Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04692675 | Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer | recruiting | N/A | 508 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06465966 | UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning | recruiting | N/A | 30 | University of FloridaOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06582017 | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | recruiting | Phase 1 | 100 | Nammi Therapeutics IncINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07050433 | COMPASS Study for Metastatic Castration-resistant Prostate Cancer | recruiting | — | 48 | Duke UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07184970 | PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound | recruiting | — | 60 | NYU Langone HealthOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07590934 | Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer(PROSPECTOR) | recruiting | Phase 1 / Phase 2 | 152 | AstraZenecaINDUSTRY | 7 | Aug 27, 2026 | clinicaltrials |
| NCT07698535 | Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial | recruiting | Phase 2 | 64 | University of WashingtonOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT02871726 | Transrectal Ultrasound Robot-Assisted Prostate Biopsy | recruiting | N/A | 483 | Johns Hopkins UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06714630 | The PROSECCA Study, Answering New Questions in Prostate Cancer(PROSECCA) | recruiting | — | 15,000 | University of EdinburghOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06960798 | Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) | recruiting | — | 150 | University of OklahomaOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07611110 | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)(VECTRA-01) | recruiting | Phase 3 | 670 | AstraZenecaINDUSTRY | 20 | Aug 26, 2026 | clinicaltrials |
| NCT07788625 | ¹⁸F-PSMA-1007 PET-CT-Directed Focal Therapy for MRI-Invisible Prostate Cancer(FOCUS-PSMA) | recruiting | N/A | 60 | The University of Hong KongOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06022822 | Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial | recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06085664 | A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy | recruiting | Phase 1 / Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07316686 | Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma | recruiting | Phase 1 | 18 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07745361 | Study of Oral MRT-2359 With Apalutamide in Prostate Cancer(MODeFIRe-1) | recruiting | Phase 2 | 25 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04221542 | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 479 | AmgenINDUSTRY | 10 | Aug 21, 2026 | clinicaltrials |
| NCT05805371 | PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 21 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06369246 | PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer. | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06844383 | A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide(TALENT) | recruiting | Phase 2 | 126 | Prostate Cancer Clinical Trials ConsortiumOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07454603 | A Single-arm, Multicenter Prospective Study to Evaluate the Diagnostic Performance of PROSTest in Men With PSA ≥ 3ng/ml Using Biopsy as the Sole Ground Truth(PROSTest_STRAT) | recruiting | — | 1,500 | Wren Laboratories LLCINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04945642 | High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma(HYDRA) | recruiting | N/A | 52 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06785636 | A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC(P300) | recruiting | Phase 1 / Phase 2 | 120 | Pathos AI, Inc.INDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06864533 | Adjuvant Chemotherapy for High Malignant Prostate Cancer(PKUFH-GS5) | recruiting | — | 315 | Peking University First HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06945172 | Comparison of Prostate Cancer-related Quality of Life in Sexually Active Men With Favourable Intermediate-risk Localised Prostate Cancer Treated With Total Prostatectomy or Focal HIFU(QUALIFY) | recruiting | N/A | 102 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Aug 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Sep 2, 2026source: clinicaltrials